# The role of magnesium sulfate in tracheal intubation without muscle relaxation in patients undergoing ophthalmic surgery

Hassan-Ali Soltani<sup>1,2,3</sup>, Seyed Jalal Hashemi<sup>2,3</sup>, Kamran Montazeri<sup>2,3</sup>, Alireza Dehghani<sup>4</sup>, Mehdi Nematbakhsh<sup>1,5</sup>

<sup>1</sup>Water and Electrolytes Research Center, Isfahan University of Medical Sciences, <sup>2</sup>Anesthesiology and Intensive Care Research Center, Isfahan University of Medical Sciences, <sup>3</sup>Department of Anesthesiology, School of Medicine, Isfahan University of Medical Sciences, <sup>4</sup>Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, <sup>5</sup>Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Background: Muscle relaxant agents usually use to facilitate tracheal intubation; however, sometimes limitations exist. Magnesium (Mg) sulfate is a candidate for muscle relaxant substitute. This study was designed to determine the effect of Mg sulfate accompanied with propofol and fentanyl in patients undergoing ophthalmic surgery. Materials and Methods: In a double-blind randomized protocol and before tracheal intubation, Mg sulfate 40, 45, or 50 mg/kg in 100 ml of saline (Groups 1-3, respectively) or saline alone (Group 4) were administrated intravenously in 100 patients (n=25 in each group) with the American Society of Anesthesiologist (ASA) physical Status I, II, or III. The patients' intubation condition in all subjects were determined and described. Results: The patients' demographic data including age, ASA, systolic and diastolic blood pressures, intraocular pressure, and body mass index were not significantly different between the groups. A better mask ventilation feasibility in Mg sulfate 45 group (Group 45) was observed when compared with Mg sulfate 450 (Group 450) (

**Key words:** Anesthesia, magnesium sulfate, tracheal intubation

How to cite this article: Soltani HA, Hashemi SJ, Montazeri K, Dehghani A, Nematbakhsh M. The role of magnesium sulfate in tracheal intubation without muscle relaxation in patients undergoing ophthalmic surgery. J Res Med Sci 2016;21:96.

## **INTRODUCTION**

Magnesium (Mg) is one of the most common cations in the intracellular fluid space that inhibits calcium entry into cell via blockade of N-methyl-D-aspartate (NMDA) receptor. [11] Mg has analgesic, anesthetic, and muscular relaxant effects. [2-4] NMDA receptor and Mg play an important role in pain pathway and control. [5] The previous studies have been demonstrated that Mg sulfate had effective role in eclampsia, [6-8] and intravenous administration of Mg sulfate also has preventive role in postoperative hyperalgesia. [9-11]

Access this article online

Quick Response Code:

Website:

www.jmsjournal.net

DOI:

10.4103/1735-1995.193168

Neuromuscular blocking agents are usually used during anesthesia to facilitate tracheal intubation. However, they are accompanied with some side effect, and it is extremely important for the anesthesiologist to have an appropriate tracheal intubation without using neuromuscular blocking agents. Aissaoui *et al.* designed a double-blind study in patient with American Society of Anesthesiologists (ASAs) I and II, and they reported that Mg sulfate improved intubation without using the neuromuscular blocking drug. [12] Hans *et al.* concluded that intravenous administration of 50 mg/kg of Mg reduced the train-of-four ratio in patients when compared with control group. [13]

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Address for correspondence: Prof. Mehdi Nematbakhsh, Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran. Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan, Iran. E-mail: nematbakhsh@med.mui.ac.ir

Received: 04-02-2016; Revised: 14-03-2016; Accepted: 18-07-2016

In patient undergoing thyroidectomy, 30 mg/kg of Mg sulfate administration prevented remifentanil-induced hyperalgesia<sup>[14]</sup> while in patient undergoing thoracotomy, a bolus dose of 30–50 mg/kg of Mg sulfate followed by continuous dose of 500 mg/h during the operation reduced intraoperative analgesic requirement.<sup>[15]</sup> It is suggested to find the role of Mg intracheal intubation old patients.<sup>[12]</sup> Therefore, this study was designed to determine the effect of Mg sulfate accompanied with propofol and fentanyl as anesthesia induction in 60–85-year-old patients undergoing ophthalmic surgery.

#### **MATERIALS AND METHODS**

This study was designed as a double-blind clinical trial in 100 patients undergoing ophthalmic surgery in Feiz Hospital during the year of 2013, and it was approved by Isfahan University of Medical Sciences Ethic Committee. Written informed consent was obtained from each patient after introduce them with study detail and design. The including criteria was 60-85 years old, physical Status of I, II, or III based on ASA, Class of 1, 2, or 3 from modified Mallampati test, Class of 1, 2, or 3 from upper lip bite test (ULBT), body mass index (BMI) between 20 and 30, and thyromental distance (TMD) >6.5 cm. As excluding criteria, the patients with a history of hyper reactive airways disease, treatment with calcium channel blockers, renal, cardiovascular, respiratory or hepatic diseases, or allergy to any of study drugs were excluded from the study. All patients were in non per oral (NPO) condition for 8 h, and during this period they were received 1/3–2/3 crystalloid solution based on 4, 2, 1 law. They were subjected to Mallampati test, ULBT and TMD determination. The Mallampati class was assessed by asking the patients in sitting posture to open his/her mouth and protrude the tongue as much as possible. The Mallampati classes were classified as Class 1: Soft palate, uvula, fauces, pillaris visible; Class 2: Soft palate, uvula, fauces visible; Class 3: Soft palate, base of uvula visible, and Class 4: Only hard palate visible. ULBT was achieved by asking the patients to bite their upper lip with lower incisor, and it was categorized as Class 1: Lower incisor can hide mucosa of the upper lip; Class 2: Lower incisor can partially hide mucosa of the upper lip, and Class 3: Lower incisor unable to touch mucosa of upper lip. The TMD was measured from the thyroid notch to the tip of the jaw with head extended. Blood samples were obtained before the operation for determination of serum Mg. Before and during the operation, all patients were monitored via electrocardiogram, heart rate (HR), oxygen saturation, and noninvasive blood pressure; systolic blood pressure (SBP) and diastolic blood pressure (DBP) determination.

The patients were randomly divided into four groups using the random table numbers list. The first number was

assigned to the first group and so on. The randomization and drug infusion were blind for the anesthesiologist. Before infusion of any drugs, intraocular pressure (IOP) was measured and recorded (Applanation Tono-Pen, Avia, Reichert Inc., Depew, NY, USA). The patients (total = 100) received 40 (Group 1, n = 25), 45 (Group 2, n = 25), 50 (Group 3, n = 25) mg/kg of Mg sulfate in 100 ml of saline, and saline alone (Group 4, n = 25). The infusion time for Mg sulfate/or saline was 10 min, and 7 min after the beginning of Mg sulfate infusion fentanyl (3 µg/kg) was administrated intravenously in the period of 3 min accompanied with oxygenation. Finally, propofol (2.5 mg/kg) was infused intravenously in 15 s, and 1 min later, the patient was subjected to tracheal intubation. The time from laryngoscope entrance to the end of tracheal intubation was recorded. Ten min after tracheal intubation, the second blood sample for Mg determination was obtained. The serum level of Mg was measured by an autoanalyzer using Pars Azmoon (Tehran, Iran) kit.

## Statistical analysis

Based on the previous study, the acceptable intubation condition (IC) in was  $60\%^{[12]}$  and need to improve to 90% by Mg sulfate. Therefore, at 5% level of significant and 75% power, using the following formula including  $Z_{1-\alpha/2}=1.96$ ,  $Z_{1-8}=0.67$ ,  $P_1=0.9$  and  $P_2=0.60$ , to estimate the sample size.

$$n = (Z_{1-\alpha/2} + Z_{1-\beta})^2 \left(P_1 \left[1 - P_1\right] + P_2 \left[1 - P_2\right]\right) / (P_1 - P_2)^2$$

Accordingly, at least 25 patients were needed in each group. Data for age, BMI, IOP, TMD, SBP, DBP, HR, and laryngoscopic time (LT) [Tables 1 and 2], and for Mg [Figure 1] were reported as a mean  $\pm$  standard deviation. These data were analyzed using one-way analysis of variance (ANOVA) and least significance difference as post. Other data reported as percent of occurrences. Based on analysis needs test. Chi-square, Kruskal–Wallis test or Mann–Whitney U-test, P < 0.05 was considered statistically significant.

## **RESULTS**

# Patients' characteristics and demographic data

The patients' characteristics and demographic data in four groups of patients are tabulated in Table 1. There are no significant differences between the groups. The patients from all groups were candidate for surgery of cataract, strabismus, retina, dacryocystorhinostomy, deep vitrectomy or corneal transplantation with no significant difference between the groups in kind of surgery (P = 0.59).

## Patients' intubation condition

The patients' IC in four groups of patients is tabulated in Table 2. A better mask ventilation feasibility (MVF)


Table 1: The patients' characteristics and demographic data in four groups of patients P **Parameter** Group 1 Ma Group 2 Ma Group 4 Group 3 Ma sulfate 40 (%) sulfate 45 (%) sulfate 50 (%) saline (%) 70.2±7.8 0.70 Age (year) 68.5±7.7 68.7±6.9 67.5±9.7 Sex (female/male) 10/15 (40/60) 13/12 (52/48) 13/12 (52/48) 10/15 (40/60) 0.69 24.8±2.7 0.69 BMI (kg/m²) 24.5±3.5 24.5±3.2 24.3±3.5 ASA (I/II/III) 6/17/2 (24/68/8) 4/19/2 (16/76/8) 4/20/1 (16/80/4) 1/22/2 (4/88/8) 0.43 IOP (mmHg) 17.7±3.9 18.2±4.0 16.9±3.6 16.6±3.7 0.47 14/11/0 (56/44/0) Mallampati classes (I/II/III) 12/12/1 (48/48/4) 13/12/0 (52/48/0) 11/14/0 (44/56/0) 0.59 ULBT (I/II/III) 18/6/1 (72/24/4) 17/7/1 (68/28/4) 16/9/0 (64/36/0) 17/6/2 (68/24/8) 0.68 TMD (cm)  $7.0\pm0.4$ 7.2±0.6 7.1±0.6 7.3±0.7 0.39 SBP (mmHg) 147.4±31.5 134.0±16.9 139.0±23.0 132.8±17.8 0.10 DBP (mmHg) 85.0±15.2 81.3±15.5  $80.8 \pm 10.6$ 78.3±8.5 0.33 79.5±14.1 HR (beat/min) 77.9 + 12.282.7±14.2 77.2+11.8 0.46

ANOVA test was used for the parameters of age, BMI, IOP, TMD, SBP, DBP, and HR. For others parameters, Chi-square was applied. BMI = Body mass index; ASA = American Society of Anesthesiologists; IOP = Intraocular pressure; ULBT = Upper lip bite test; TMD = Thyromental distance; SBP = Systolic blood pressure; DBP = Diastolic blood pressure; HR = Heart rate; ANOVA = Analysis of variance; Mg = Magnesium

	Table 2: The	patients' intubation	condition in four ar	ouns of nationts
--	--------------	----------------------	----------------------	------------------

Parameter	Group 1 (%)	Group 2 (%)	Group 3 (%)	<b>Group 4 (%)</b>	P
MVF (I/II/III)	23/2/0 (92/8/0)	24/1/0 (96/4/0)	18/7/0# (72/28/0)	18/6/1# (72/24/4)	0.03
LD (I/II/III)	17/7/1 (68/28/4)	19/5/1 (76/20/4)	18/6/1 (72/24/4)	15/7/3 (60/28/12)	0.58
CL (I/II/III/IV)	17/7/1/0 (68/28/4/0)	17/8/0/0 (68/32/0/0)	20/4/1/0 (80/16/4/0)	20/3/1/1 (80/12/4/4)	0.71
IC (I/II/III)	15/10/0 (60/40/0)	14/9/2 (56/36/8)	11/14/0 (44/56/0)	11/8/6 (44/32/24)	0.32
VCM (I/II/III)	14/11/0 (56/44/0)	14/11/0 (56/44/0)	13/10/2 (52/40/8)	5/9/11* <sup>,#,†</sup> (20/36/44)	< 0.0001
ITR (0/I/II/III)	1/3/8/13 (4/12/32/52)	12/7/3/3 (48/28/12/12)	6/10/5/4 (24/40/20/16)	8/6/4/7 (32/24/16/28)	0.15
MRR, n (%)	0	0	1 (4)	11 (44)*,#,†	< 0.0001
LT (s)	8.6±2.3	9.2±3.3	9.7±2.2	14.2±5.8*, <sup>#</sup> ,†	< 0.0001

Significant difference from \*Group 1, #Group 2, or 'Group 3 (P<0.05). ANOVA test followed by LSD as posttest for LT, Kruskal-Wallis test, and Mann-Whitney U-test (to compare each two groups) tests for MRR and Chi-square for the other parameters were used. MVF = Mask ventilation feasibility; LD = Laryngoscopic difficulty; CL = Cormack-Lehane; IC = Intubation condition; ITR = Intubation response; VCM = Vocal cord movement; MRR = Muscle relaxant requirement; LT = Laryngoscopic time; LSD = Least significance difference; ANOVA = Analysis of variance



**Figure 1:** The serum level of magnesium before and after tracheal intubation in patients. The star indicates significant difference from Group 4 using one-way analysis of variance (P < 0.0001)

in Mg sulfate 45 group (Group 2) was observed when compared with Mg sulfate 50 group (Group 3) (P = 0.022) and Group 4 (saline group) (P = 0.021). No significant differences were detected in laryngoscopic difficulty (LD), Cormack–Lehane (CL) classifications, IC classifications, and intubation response (ITR) classifications between the groups. However, the vocal cord movement (VCM) and muscle relaxant requirement (MRR) in Group 4 was

significantly different from others groups (P < 0.05); that mean MRR was greater in Group 4 than other groups. The LT in Group 4 also was greater than other groups significantly (P < 0.0001).

## Patients' hemodynamic condition

The average reduction of IOP after tracheal intubation was  $5.2 \pm 4.1$  mmHg with no significant differences between the groups. The data for SBP, DBP, and HR in all the patients were tabulated in Table 1, and no significant differences were observed between the groups.

#### Patients' serum level of magnesium

The serum level of Mg before and 10 min after the end of Mg sulfate or saline infusion is demonstrated in Figure 1. Before infusion, the serum level of Mg were  $1.86 \pm 0.18$ ,  $1.89 \pm 0.32$ ,  $1.83 \pm 0.22$ ,  $1.89 \pm 0.21$  mg/dl in Groups 1-4, respectively. However, it reached to  $2.70 \pm 0.32$ ,  $2.65 \pm 0.35$ ,  $2.56 \pm 0.21$ , and  $1.82 \pm 0.0.40$  mg/dl accordingly. No significant differences were obtained before Mg sulfate/or saline infusion between the groups. However, the serum level of Mg in saline group (Group 4) was less than other groups significantly after intubation (P < 0.0001).

# **DISCUSSION**

The main objective of this study was to determine the effect of different dose of Mg accompanied with propofol and fentanyl as anesthesia induction in 60-85-year-old patients undergoing ophthalmic surgery. Our finding indicated that MVF qualification was better in Mg sulfate 45 group (Group 2). This factor was not determined in Aissaoui et al. study.[12] However, similar result to Aissaoui et al. study was found for VCM data indicating the positive effect role of Mg sulfate during laryngoscopy. Each dose of Mg sulfate caused the lesser needs of MRR. Similar to our study, Hans et al. used rocuronium for tracheal intubation, and they reported that administration of Mg reestablishes the degree of muscle paralysis. [13] Other study demonstrated that 10 and 20 mg/kg of Mg before rocuronium reduced the overall movement in patients.[16] On the contrary, some of our findings such as LD, CL, IC, or ITR are different from other studies, [12,13] and possibly the non-similarity is related to our study power. Regarding hemodynamics response, we did not find a significant decrease in SBP, DBP, or HR after drugs infusion and after anesthesia induction while Puri et al. showed that Mg sulfate infusion reduced mean arterial pressure by 17%.[17] Similar to our results, Aissaoui et al. study also did not indicate any significant difference in HR and mean arterial pressure between Mg sulfate receiver and control groups.[12] Mg sulfate administration increased the serum level of Mg after intubation. However, no significant difference in serum level of Mg was observed when different doses of Mg sulfate (40, 45, or 50 mg/kg) were infused. Aissaoui et al. did not measured the serum level of Mg,[12] but other studies demonstrated that Mg sulfate (50 mg/kg) increase the serum level of Mg. [18,19] In our study, the serum level of Mg was increased about 40% which is not clinically significant with any adverse effect.[11]

## **CONCLUSION**

When clinical limitation is existed to use muscle relaxant, intravenous infusion of Mg sulfate could be a choice to facilitate tracheal intubation, and the infused Mg sulfate does not elevate the plasma level of Mg to clinical significant.

## Acknowledgments

The authors thank Ms. F. Eshraghi and Mrs. V. Salimi for their significant assistance.

# Financial support and sponsorship

This research was supported by Isfahan University of Medical Sciences (Grant number: 292191).

## **Conflicts of interest**

There are no conflicts of interest.

# **AUTHORS' CONTRIBUTION**

HAS was involved in study design, collecting the data and in preparing the article. SJH was involved in study design, collecting the data and in preparing the article and data analysis. KM and AD contributed equally for data collection and preparing the article. MN was involved in study design, part of laboratory data collection, data analysis and preparing the final draft of the article.

#### **REFERENCES**

- 1. Soave PM, Conti G, Costa R, Arcangeli A. Magnesium and anaesthesia. Curr Drug Targets 2009;10:734-43.
- Herroeder S, Schönherr ME, De Hert SG, Hollmann MW. Magnesium – Essentials for anesthesiologists. Anesthesiology 2011;114:971-93.
- Dubé L, Granry JC. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: A review. Can J Anaesth 2003;50:732-46.
- 4. Fawcett WJ, Haxby EJ, Male DA. Magnesium: Physiology and pharmacology. Br J Anaesth 1999;83:302-20.
- Begon S, Pickering G, Eschalier A, Mazur A, Rayssiguier Y, Dubray C. Role of spinal NMDA receptors, protein kinase C and nitric oxide synthase in the hyperalgesia induced by magnesium deficiency in rats. Br J Pharmacol 2001;134:1227-36.
- Duley L, Gülmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010;(11):CD000025. doi: 10.1002/14651858.CD000025.pub2.
- Dennis AT. Management of pre-eclampsia: Issues for anaesthetists. Anaesthesia 2012;67:1009-20.
- 8. Turner JA. Diagnosis and management of pre-eclampsia: An update. Int J Womens Health 2010;2:327-37.
- 9. Song JW, Lee YW, Yoon KB, Park SJ, Shim YH. Magnesium sulphate preventing post-operative hyperalgesia. Anesth Analg. 2011;113(2):390-7. doi: 10.1213/ANE.0b013e31821d72bc. Epub 2011 May 19.
- Na HS, Lee JH, Hwang JY, Ryu JH, Han SH, Jeon YT, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth 2010;104:344-50.
- Lysakowski C, Dumont L, Czarnetzki C, Tramèr MR. Magnesium as an adjuvant to postoperative analgesia: A systematic review of randomized trials. Anesth Analg 2007;104:1532-9.
- Aissaoui Y, Qamous Y, Serghini I, Zoubir M, Salim JL, Boughalem M. Magnesium sulphate: An adjuvant to tracheal intubation without muscle relaxation – A randomised study. Eur J Anaesthesiol 2012;29:391-7.
- Hans GA, Bosenge B, Bonhomme VL, Brichant JF, Venneman IM, Hans PC. Intravenous magnesium re-establishes neuromuscular block after spontaneous recovery from an intubating dose of rocuronium: A randomised controlled trial. Eur J Anaesthesiol 2012;29:95-9.
- 14. Song JW, Lee YW, Yoon KB, Park SJ, Shim YH. Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. Anesth Analg 2011;113:390-7.
- 15. Kogler J. The analgesic effect of magnesium sulfate in patients undergoing thoracotomy. Acta Clin Croat 2009;48:19-26.
- 16. Shin YH, Choi SJ, Jeong HY, Kim MH. Evaluation of dose effects of magnesium sulfate on rocuronium injection pain

- and hemodynamic changes by laryngoscopy and endotracheal intubation. Korean J Anesthesiol 2011;60:329-33.
- 17. Puri GD, Marudhachalam KS, Chari P, Suri RK. The effect of magnesium sulphate on hemodynamics and its efficacy in attenuating the response to endotracheal intubation in patients with coronary artery disease. Anesth Analg 1998;87:808-11.
- 18. Apan A, Buyukkocak U, Ozcan S, Sari E, Basar H. Postoperative magnesium sulphate infusion reduces analgesic requirements in spinal anaesthesia. Eur J Anaesthesiol 2004;21:766-9.
- 19. Ko SH, Lim HR, Kim DC, Han YJ, Choe H, Song HS. Magnesium sulfate does not reduce postoperative analgesic requirements. Anesthesiology 2001;95:640-6.